ResMed Inc.

NYSE:RMD Lagerbericht

Marktkapitalisierung: US$36.0b

ResMed Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ResMed wird ein jährliches Gewinn- und Umsatzwachstum von 11.5% bzw. 6.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.9% betragen.

Wichtige Informationen

11.5%

Wachstumsrate der Gewinne

11.4%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum17.7%
Wachstumsrate der Einnahmen6.5%
Zukünftige Eigenkapitalrendite21.9%
Analystenabdeckung

Good

Zuletzt aktualisiert30 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Aug 05
ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Jul 29
Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

Jul 15
Returns On Capital Are A Standout For ResMed (NYSE:RMD)

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Jul 03

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30
Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18
ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22
With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10
Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20
ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06
Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10
Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01
Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07
ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30
ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16
Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02
A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26
We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24
ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09
Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26
A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

ResMed goes ex dividend tomorrow

Feb 07

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Feb 06
ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Gewinn- und Umsatzwachstumsprognosen

NYSE:RMD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
6/30/20275,7361,5611,5451,67715
6/30/20265,3971,4331,4631,57520
6/30/20255,0461,2971,2061,35921
6/30/20244,6851,0211,2861,401N/A
3/31/20244,5849581,0711,199N/A
12/31/20234,5048909441,079N/A
9/30/20234,375907792935N/A
6/30/20234,223898559693N/A
3/31/20234,016863408535N/A
12/31/20223,763809222370N/A
9/30/20223,624786305461N/A
6/30/20223,578779195351N/A
3/31/20223,539779344498N/A
12/31/20213,444522446577N/A
9/30/20213,349500397527N/A
6/30/20213,197475620737N/A
3/31/20213,091457733840N/A
12/31/20203,092699774884N/A
9/30/20203,028680684784N/A
6/30/20202,957622696802N/A
3/31/20202,892513505614N/A
12/31/20192,784455420514N/A
9/30/20192,699419487573N/A
6/30/20192,607405382459N/A
3/31/20192,525446374447N/A
12/31/20182,455450385456N/A
9/30/20182,405335390459N/A
6/30/20182,340316434505N/A
3/31/20182,273307N/A516N/A
12/31/20172,196285N/A434N/A
9/30/20172,125352N/A422N/A
6/30/20172,067342N/A414N/A
3/31/20172,029324N/A417N/A
12/31/20161,968327N/A474N/A
9/30/20161,893346N/A510N/A
6/30/20161,839352N/A548N/A
3/31/20161,773357N/A505N/A
12/31/20151,742357N/A471N/A
9/30/20151,710353N/A421N/A
6/30/20151,679353N/A383N/A
3/31/20151,641353N/A399N/A
12/31/20141,616352N/A409N/A
9/30/20141,578348N/A387N/A
6/30/20141,555345N/A391N/A
3/31/20141,554331N/A400N/A
12/31/20131,540325N/A406N/A
9/30/20131,532317N/A415N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RMDDas prognostizierte Gewinnwachstum (11.5% pro Jahr) liegt über der Sparquote (2.5%).

Ertrag vs. Markt: RMDDie Erträge des Unternehmens (11.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.2% pro Jahr).

Hohe Wachstumserträge: RMDDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: RMDDie Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: RMDDie Einnahmen des Unternehmens (6.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RMDDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.9%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y